Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

KalVista Pharmaceuticals, Inc. will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational ...

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes ...

Quanterix Corporation , a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech / pharma companiesAddressing large and ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and gro ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Here’s the latest company planning for gene-edited babies The news: A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create ...